Recent buy – AbbVie – April 2019

A new buy for my Vrijheid Fonds, I bought some shares of AbbVie.

I was looking at several stocks the last couple of weeks.  And I did some research in some stocks. After some thinking and some checking which stock is hot in our FIRE community, I made a decision.


This week I made my first buy in 2019 for my Vrijheid Fonds.

After my analysis of AbbVie, I decided to pull my buy-trigger. If you haven’t read my analysis, please take a look at this post about AbbVie Stock Analysis Polliestyle – 2019



This week I bought 25 shares of ABBV at $ 82.33 per share (incl. fees).

With this buyI added a little bit more than € 60 (after taxes) of projected dividend to my Vrijheid Fonds.

The projected dividend income for 2019 for my Vrijheid Fondsis €3,919.

Again a small step in my journey and one-step closer to my goal. Has anyone else invested in this company recently? I appreciate any feedback!




Disclaimer: I’m not a registered investment adviser, investment professional, brokerage firm or investment company. Readers are advised that information on the website is issued solely for information purposes and not to be construed as an offer or recommendation to buy, hold, or sell any securities. All information, opinions, and analyses included are based on sources believed to be reliable, but no representation or warranty is made concerning accuracy, correctness, timeliness, or appropriateness. Please consult with an investment professional before investing any of your money.


7 thoughts on “Recent buy – AbbVie – April 2019

  1. dividendcompounder

    Wow, that’s quite a large purchase! I like to buy more below the $80 mark. I’m very confident about the product pipeline jnstead of many writers who think this company is a one-trick pony.

    Congratulations and happy investing! 👍

  2. Jung in Rente

    Hey Pollie,

    Congrats! AbbVie looks like a great addition to your existing portfolio.

    I already liked your thorough analysis from March, when you almost came to the same conclusion than I did in my Snapshot in January (https://www.dividenddiary.com/abbvie-snapshot/).

    However, I’m still a bit worried that AbbVie won’t be able to compensate the losses resulting from its patent expirations. I guess that’s why I haven’t initiated a position yet.

    – David

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.